Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0024530 (
malaria
)
44,886
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Plasmodium sporozoites develop within oocysts in the mosquito midgut wall and then migrate to the salivary glands. After transmission, they embark on a complex journey to the mammalian liver, where they infect hepatocytes. Proteins on the sporozoite surface likely mediate multiple steps of this journey, yet only a few sporozoite surface proteins have been described. Here, we characterize a novel, conserved sporozoite surface protein (
SSP3
) in the rodent
malaria
parasite Plasmodium yoelii.
SSP3
is a putative type I transmembrane protein unique to Plasmodium. By using epitope tagging and
SSP3
-specific antibodies in conjunction with immunofluorescence microscopy, we showed that
SSP3
is expressed in mosquito midgut oocyst sporozoites, exhibiting an intracellular localization. In sporozoites derived from the mosquito salivary glands, however,
SSP3
localized predominantly to the sporozoite surface as determined by immunoelectron microscopy. However, the ectodomain of
SSP3
appeared to be inaccessible to antibodies in nonpermeabilized salivary gland sporozoites. Antibody-induced shedding of the major surface protein circumsporozoite protein (CSP) exposed the
SSP3
ectodomain to antibodies in some sporozoites. Targeted deletion of
SSP3
adversely affected in vitro sporozoite gliding motility, which, surprisingly, impacted neither their cell traversal capacity, host cell invasion in vitro, nor infectivity in vivo. Together, these data reveal a previously unappreciated complexity of the Plasmodium sporozoite surface proteome and the roles of surface proteins in distinct biological activities of sporozoites.
...
PMID:SSP3 is a novel Plasmodium yoelii sporozoite surface protein with a role in gliding motility. 2515 33